70 related articles for article (PubMed ID: 1877838)
21. Treatment of malignant melanoma with interleukin-2.
Philip PA; Flaherty L
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
[TBL] [Abstract][Full Text] [Related]
22. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2.
Velotti F; Stoppacciaro A; Ruco L; Tubaro A; Pettinato A; Morrone S; Napolitano T; Bossola PC; Franks CR; Palmer P
Cancer Res; 1991 May; 51(9):2456-62. PubMed ID: 2015606
[TBL] [Abstract][Full Text] [Related]
23. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
24. [Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
Kimura H; Yamaguchi Y; Obata S; Yusa T; Sekine Y
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2401-4. PubMed ID: 3137876
[TBL] [Abstract][Full Text] [Related]
25. [A case of metastatic splenic tumor treated with intra-arterial immunochemotherapy to induce endogenous LAK cell].
Ogawara T; Sekikawa T; Kouno K; Matsumoto Y
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1446-9. PubMed ID: 7690534
[TBL] [Abstract][Full Text] [Related]
26. [Augmentation of cytotoxicity of nonparenchymal cell of the liver after continuous IL-2 administration via the portal vein].
Shimoda K; Oka M; Hazama S; Suzuki M; Lizuka N; Wadamori K; Wang F; Suzuki T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1567-9. PubMed ID: 8373220
[TBL] [Abstract][Full Text] [Related]
27. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
Blancher A; Roubinet F; Grancher AS; Tremoulet M; Bonaté A; Delisle MB; Calot JP; Pourreau C; Franks C; Ducos J
Eur Cytokine Netw; 1993; 4(5):331-41. PubMed ID: 8117934
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of continuous infusion of recombinant interleukin-2.
West WH
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
[TBL] [Abstract][Full Text] [Related]
30. [Continuous arterial infusion therapy of recombinant interleukin-2 and cyclophosphamide in hepatoma and liver metastasis].
Hayakawa K; Fukushima T; Seito D; Asakura Y; Yamanaka Y; Morita T; Sasaki M; Konn M; Ono K
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2842-4. PubMed ID: 2551226
[TBL] [Abstract][Full Text] [Related]
31. [An experimental study on the in vivo induction of lymphokine activated killer (LAK) cells by the continuous infusion of interleukin 2 (IL-2) through the splenic artery].
Ohnishi H
Nihon Gan Chiryo Gakkai Shi; 1988 Dec; 23(11):2785-93. PubMed ID: 3266874
[No Abstract] [Full Text] [Related]
32. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.
Mavligit GM; Zukiwski AA; Gutterman JU; Salem P; Charnsangavej C; Wallace S
J Clin Oncol; 1990 Feb; 8(2):319-24. PubMed ID: 2405108
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of recombinant human interleukin-2 on the growth of murine hemangioendothelioma D14 in nude mice: occurrence of large granular cells in the tumor.
Sakura Y; Houkan T; Ootsu K; Shino A
Jpn J Cancer Res; 1991 Aug; 82(8):950-7. PubMed ID: 1910031
[TBL] [Abstract][Full Text] [Related]
34. Local administration trials of interleukin-2 for head and neck cancer.
Saito T; Yoda J; Tabata T
Auris Nasus Larynx; 1991; 18(2):169-78. PubMed ID: 1741710
[TBL] [Abstract][Full Text] [Related]
35. A case of malignant haemangioendothelioma treated with recombinant interleukin-2.
Ansai S; Goto K; Aoki T; Hozumi Y; Aso K
Clin Exp Dermatol; 1993 Sep; 18(5):470-5. PubMed ID: 8252775
[TBL] [Abstract][Full Text] [Related]
36. [Successful immunotherapy of malignant hemangioendothelioma using recombinant interleukin-2].
Masuzawa M; Higashi K; Nishioka K; Nishiyama S
Nihon Hifuka Gakkai Zasshi; 1988 Mar; 98(3):367-9. PubMed ID: 3261813
[No Abstract] [Full Text] [Related]
37. Malignant hemangioendothelioma.
Ihda H; Tokura Y; Fushimi M; Yokote R; Hashizume H; Shirahama S; Iwatsuki K; Murakami K; Takigawa M
Int J Dermatol; 1995 Nov; 34(11):811-6. PubMed ID: 8543420
[TBL] [Abstract][Full Text] [Related]
38. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.
Clayman GL; Liu FJ; Savage HE; Taylor DL; Lavedan P; Buchsbaum RM; Pellegrino C; Trujillo JM; Young G; Schantz SP
Arch Otolaryngol Head Neck Surg; 1992 Jan; 118(1):41-8. PubMed ID: 1370199
[TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of local administration of RIL-2 in head and neck cancer].
Saito T; Kakiuti H; Kuki K; Yokota M; Jinnin T; Kimura T; Fujiwara K; Yoda J; Kunimoto M; Arai H
Nihon Jibiinkoka Gakkai Kaiho; 1989 Aug; 92(8):1265-70. PubMed ID: 2585201
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous malignant hemangioendothelioma: clinical and histopathological observations of nine patients and a review of the literature.
Bhutto AM; Uehara K; Takamiyagi A; Hagiwara K; Nonaka S
J Dermatol; 1995 Apr; 22(4):253-61. PubMed ID: 7608382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
